Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Division of Health Information, Israel Ministry of Health, Jerusalem, Israel.
Vaccine. 2020 Feb 28;38(10):2406-2415. doi: 10.1016/j.vaccine.2020.01.034. Epub 2020 Feb 3.
In December 2010, the pentavalent rotavirus vaccine (RotaTeq) was added to the national immunization program in Israel. The study aim was to examine national reductions in all-cause acute gastroenteritis (AGE) and rotavirus gastroenteritis (RVGE) hospitalizations among children aged 0-59 months following the introduction of universal rotavirus immunization in Israel.
We extracted data from the Israel National Hospital Discharge Database. Hospitalization rates were calculated by dividing the annual number of all-cause AGE and RVGE hospitalizations by the number of children aged 0-59 months residing Israel. To assess rate reductions, we compared the mean hospitalization rate for the pre-vaccine years (2002-2008) with that for the universal vaccination years (2011-2017). Interrupted time-series analyses were undertaken. During 2008-2010 rotavirus vaccines were partially available.
A total of 131,116 AGE hospitalizations were reported, of which 13,111 (10.0%) were coded as RVGE hospitalizations. The average annual all-cause AGE hospitalization rate during the pre-vaccine period was 147.9 (95% CI 146.7-149.0) per 10,000 children aged 0-59 months, and declined by 38.7-53.0% during the universal vaccination years. The average annual pre-vaccine RVGE hospitalization rate was 16.9 (95% CI 16.5-17.3) per 10,000 children, and declined by 89.1% during 2016-2017. Findings from interrupted time-series analyses showed significant impact of introducing universal rotavirus immunization on the declines of all-cause AGE and RVGE hospitalizations rates. A multivariable Autoregressive Integrated Moving Average model showed that the variable "immunization period" was a significant predictor of RVGE hospitalizations (t = 7.3, p < 0.001) for the universal vaccination years. The declines in hospitalizations rates of all-cause AGE were lower among Arab children compared to Jewish children, but the declines in RVGE rates were similar between the groups.
National hospitalization data demonstrated substantial and consistent reductions in all-cause AGE and RVGE hospitalizations following the implementation of universal rotavirus vaccination program.
2010 年 12 月,五价轮状病毒疫苗(RotaTeq)被纳入以色列国家免疫计划。本研究旨在评估在以色列普遍接种轮状病毒疫苗后,0-59 月龄儿童因所有病因急性胃肠炎(AGE)和轮状病毒胃肠炎(RVGE)住院的全国减少情况。
我们从以色列国家住院数据库中提取数据。通过将每年所有病因 AGE 和 RVGE 住院人数除以 0-59 月龄居住在以色列的儿童人数,计算住院率。为评估降低率,我们将疫苗前年份(2002-2008 年)的平均住院率与普遍接种年份(2011-2017 年)的平均住院率进行比较。进行了中断时间序列分析。在 2008-2010 年期间,轮状病毒疫苗部分可用。
共报告 131116 例 AGE 住院病例,其中 13111 例(10.0%)被编码为 RVGE 住院病例。疫苗前时期的平均年度所有病因 AGE 住院率为每 10000 名 0-59 月龄儿童 147.9(95%CI 146.7-149.0),在普遍接种年份下降 38.7-53.0%。疫苗前时期的平均年度 RVGE 住院率为每 10000 名儿童 16.9(95%CI 16.5-17.3),2016-2017 年下降 89.1%。中断时间序列分析结果表明,普遍接种轮状病毒疫苗对所有病因 AGE 和 RVGE 住院率下降具有显著影响。多变量自回归积分移动平均模型显示,“免疫期”变量是 RVGE 住院(t=7.3,p<0.001)的一个显著预测因子,普遍接种年份。与犹太儿童相比,阿拉伯儿童的所有病因 AGE 住院率下降较低,但 RVGE 率的下降在两组之间相似。
国家住院数据表明,普遍接种轮状病毒疫苗后,所有病因 AGE 和 RVGE 住院率显著且持续下降。